Top of this page
Skip navigation, go straight to the content

This section is intended for media and financial analysts
Newsroom Press Releases

UCB reports financials in line with expectations, integration completed, R&D milestones achieved and stronger focus on core business

  • Financial performance in the first half of 2008 in-line with expectations: Revenue as expected down by 11% to EUR 1.7 billion; underlying profitability (recurring EBITDA) reached EUR 358 million (-26%), reported net profit EUR 108 million (-37%).
  • Integration of Schwarz Pharma completed ahead of schedule: Synergies in the first six months reached EUR 305 million; synergies of 2008 will reach EUR 350 million; targeted synergies of EUR 380 million to be reached almost two years ahead of schedule.
  • Multiple regulatory milestones and approvals: In the first half of 2008, UCB achieved two approvals (Cimzia®, Crohn's disease and Xyzal® oral solution) in the U.S. and two positive opinions (Neupro®, RLS and Vimpat®, epilepsy) for Europe.
  • New "SHAPE" initiative: Major global effort to improve competitiveness and profitability by re-allocating EUR 300 million within the next three years. The initiative includes increased focus, re-deployment of UCB's resources, advance of R&D and simplifying the organisation while successfully delivering UCB's new medicines to patients.
  • Outlook 2008: Revenue is expected to exceed EUR 3.3 billion; underlying profitability (recurring EBITDA) 2008 is confirmed to reach approximately EUR 650 million. Net result might be significantly impacted by UCB's initiative "SHAPE".

BRUSSELS, BELGIUM - August 1st 2008 - 7:00 am CET - press release, regulated information - UCB today announced its consolidated interim financial results.

"The financial performance in the first six months is well in-line with expectations," says Roch Doliveux, CEO of UCB. "With one of the most exciting late stage pipelines in the industry and following recent approvals, like Cimzia® for Crohn's disease in the U.S., and positive opinions for Neupro® for RLS and Vimpat® for epilepsy in Europe, the time is now to further shape UCB and become a specialist company focused on successfully delivering our new medicines to patients."


Stay up-to-date on the latest news and information from UCB